Clinical Trials · NCT05027308

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

CompletedPhase 3Teduglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Takeda
Enrollment
3
Start date
Jan 2022
Locations
6 sites, Japan
Primary endpoint
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
View Teduglutide compound reference